The pharmaceutical industry is witnessing a surge in mergers and acquisitions, both internationally and within Greece, starting from late 2025 and continuing into 2026. The main objective of these deals is the acquisition of innovative medicines and products nearing the end of their patent life. Recent significant agreements include Eli Lilly's acquisition of Orna Therapeutics and Illumina's purchase of SomaLogic, along with substantial investments in areas such as obesity and rare diseases from companies like Sanofi and Pfizer.

According to industry experts, after a series of unpredictable years for merger and acquisition activity in the biopharmaceutical sector, 2025 marked a notable revitalization of investment movements particularly in biotechnology. Bart Van de Vyer, a mergers and acquisitions consultant at McKinsey, noted that while none of the recent transactions reached the historic high levels seen in previous decades, such as Takeda's $64 billion acquisition of Shire, the current trend indicates a renewed confidence and strategic focus within the market.

The implications of these mergers and acquisitions are substantial for the pharmaceutical landscape in Greece and globally. As companies strive to enhance their portfolios and competitive edge, the focus on innovative therapies and drug development is expected to drive significant changes in market dynamics, potentially improving therapeutic options for patients. However, this consolidation may also raise concerns regarding competition and access to medications, particularly in a market that might become increasingly dominated by a few large entities.